Cargando…

Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks

Abnormal aggregation of tau is the pathological hallmark of tauopathies including frontotemporal dementia (FTD). We have generated tau-transgenic mice that express the aggregation-prone P301S human tau (line 66). These mice present with early-onset, high tau load in brain and FTD-like behavioural de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwab, Karima, Melis, Valeria, Harrington, Charles R., Wischik, Claude M., Magbagbeolu, Mandy, Theuring, Franz, Riedel, Gernot
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391171/ https://www.ncbi.nlm.nih.gov/pubmed/34440931 http://dx.doi.org/10.3390/cells10082162

Ejemplares similares

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia
por: Lemke, Nora, et al.
Publicado: (2021)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
por: Kondak, Constantin, et al.
Publicado: (2023)

Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model
por: Riedel, Gernot, et al.
Publicado: (2020)

Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer’s disease and frontotemporal lobar degeneration
por: Cranston, Anna L, et al.
Publicado: (2020)

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
por: Shiells, Helen, et al.
Publicado: (2020)

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
por: Schwab, Karima, et al.
Publicado: (2018)

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
por: Wischik, Claude M., et al.
Publicado: (2022)

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
por: Melis, Valeria, et al.
Publicado: (2015)

Plasma tau is increased in frontotemporal dementia
por: Foiani, Martha S, et al.
Publicado: (2018)

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease
por: Schelter, Bjoern O., et al.
Publicado: (2019)

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration
por: Melis, V., et al.
Publicado: (2014)

Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
por: Arastoo, Mohammad, et al.
Publicado: (2023)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier
por: Bentham, Peter, et al.
Publicado: (2021)

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
por: Oakley, Sebastian S., et al.
Publicado: (2020)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
por: Wischik, Claude M., et al.
Publicado: (2018)

(18)F-MK-6240 tau-PET in genetic frontotemporal dementia
por: Levy, Jake P, et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology
por: Kühn, Rebekka, et al.
Publicado: (2021)

Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
por: Al-Hilaly, Youssra K., et al.
Publicado: (2022)

PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia
por: Radford, Helois, et al.
Publicado: (2015)

Frontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment
por: Ritter, Maxi L., et al.
Publicado: (2018)

Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia
por: Paonessa, Francesco, et al.
Publicado: (2019)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines
por: Padmanabhan, Pranesh, et al.
Publicado: (2019)

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
por: Silva, M Catarina, et al.
Publicado: (2019)

Tau physiology and pathomechanisms in frontotemporal lobar degeneration
por: Bodea, Liviu‐Gabriel, et al.
Publicado: (2016)

Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability
por: Silva, M. Catarina, et al.
Publicado: (2016)

Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics
por: Whitwell, Jennifer L., et al.
Publicado: (2012)

Young‐onset frontotemporal dementia in a homozygous tau R406W mutation carrier
por: Ng, Adeline S. L., et al.
Publicado: (2015)

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
por: Arastoo, Mohammad, et al.
Publicado: (2020)

Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia
por: Vuksanović, Vesna, et al.
Publicado: (2021)

Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
por: Gibbons, Garrett S., et al.
Publicado: (2019)

Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag
por: Karikari, Thomas K., et al.
Publicado: (2017)

[(18)F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
por: Santillo, Alexander F., et al.
Publicado: (2022)

Frontotemporal Dementia P301L Mutation Potentiates but Is Not Sufficient to Cause the Formation of Cytotoxic Fibrils of Tau
por: Wang, Kuang-Wei, et al.
Publicado: (2023)

Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation
por: Papegaey, Anthony, et al.
Publicado: (2016)

Paired Helical Filament-Forming Region of Tau (297–391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells
por: Pollack, Saskia J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m7vfmvd5t7e0bv8sokvhmr2cm9